

RECEIVED

JAN 06 2003

TECH CENTER 1600/2900

PATENT

Attorney Docket No.: 8321-116  
(Formerly DIE01-  
NP002)

#9  
MLW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of  
Bernhard Dietzhold, et al

Serial No.: 09/924,112

Filed: August 7, 2001

For: RHABDOVIRUS-BASED VECTORS  
TO EXPRESS FUNCTIONAL HUMAN  
ANTIBODIES

Group Art Unit: 1635

Examiner:  
Tara Washington

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37C.F.R. §§1.97-1.98, submitted herewith are copies of the reference listed in the accompanying Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached PTO 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

CERTIFICATE OF MAILING  
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.


BY Janie Williams

DATE: 12/31/02

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,  
BERNHARD DIETZSCHOLD, et al.

By:   
DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH, LLP.  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
(215) 988-3312  
(215) 988-2757 – Fax

Attorney for Applicants

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
**8321-116 (formerly  
DIE01-NP002)**SERIAL NO.  
**09/924,112**

## INFORMATION DISCLOSURE CITATION

APPLICANT:  
**Bernhard Dietzschold, et al**FILING DATE  
**08/07/2001**GROUP  
**1635**JAN 06 2003  
TECH CENTER 1600/2900

RECEIVED

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	2002/0107869	8/8/2002	Leroy	707	104.1	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	AB	WO99/32648	7/1/99	PCT	C12N	15/86		
	AC	WO01/88132	11/22/01	PCT	C12N	15/12		
	AD	WO96/08574	3/21/96	PCT	C12N	15/86	AA	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Morimoto, et al.: "High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector" <i>Journal of Immunological Methods</i> , Vol (252), pp. 199-206 (2001)
AF	Mebatsion, et al.: "Highly stable expression of a foreign gene from rabies virus vectors" <i>Proc. Natl. Acad. Sci.</i> Vol. 93, pp. 7310-7314, July 1996
AG	Chamoion, et al.: "The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure" <i>Journal of Immunological Methods</i> , Vol 235, pp. 81-90 (2000)
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	